Sign up
Pharma Capital

CytoDyn CEO responds to share price rise as investors get excited about leronlimab

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors he's optimistic about results the company has seen in pre-clinical studies relating to a liver disease known as NASH. However, he's not sure how much CymaBay Therapeutics Inc's (NASDAQ:CBAY) disappointing mid-stage trial results in NASH contributed to pushing up CytoDyn's stock.

Pourhassan also touches on other developments within the Washington-based company including timelines to submit its BLA and recent fundraising efforts.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.